247 related articles for article (PubMed ID: 24487969)
1. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation.
Yang L; Shi LP; Chen HJ; Tong XK; Wang GF; Zhang YM; Wang WL; Feng CL; He PL; Zhu FH; Hao YH; Wang BJ; Yang DL; Tang W; Nan FJ; Zuo JP
Acta Pharmacol Sin; 2014 Mar; 35(3):410-8. PubMed ID: 24487969
[TBL] [Abstract][Full Text] [Related]
2. Anti-hepatitis B virus activity of α-DDB-FNCG, a novel nucleoside-biphenyldicarboxylate compound in vitro and in vivo.
Yang Q; Zhao X; Yu W; He W; Fang X; Zang L; Wan N; Wang Q; Zheng L; Chang J
J Pharmacol Sci; 2014; 126(3):208-15. PubMed ID: 25409748
[TBL] [Abstract][Full Text] [Related]
3. Effect of a hepatitis B virus inhibitor, NZ-4, on capsid formation.
Yang L; Wang YJ; Chen HJ; Shi LP; Tong XK; Zhang YM; Wang GF; Wang WL; Feng CL; He PL; Xu YB; Lu MJ; Tang W; Nan FJ; Zuo JP
Antiviral Res; 2016 Jan; 125():25-33. PubMed ID: 26611395
[TBL] [Abstract][Full Text] [Related]
4. Isolation and identification of an anti-hepatitis B virus compound from Hydrocotyle sibthorpioides Lam.
Huang Q; Zhang S; Huang R; Wei L; Chen Y; Lv S; Liang C; Tan S; Liang S; Zhuo L; Lin X
J Ethnopharmacol; 2013 Nov; 150(2):568-75. PubMed ID: 24051027
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo anti-hepatitis B virus activities of the lignan niranthin isolated from Phyllanthus niruri L.
Liu S; Wei W; Shi K; Cao X; Zhou M; Liu Z
J Ethnopharmacol; 2014 Sep; 155(2):1061-7. PubMed ID: 25009077
[TBL] [Abstract][Full Text] [Related]
6. Protocatechuic aldehyde inhibits hepatitis B virus replication both in vitro and in vivo.
Zhou Z; Zhang Y; Ding XR; Chen SH; Yang J; Wang XJ; Jia GL; Chen HS; Bo XC; Wang SQ
Antiviral Res; 2007 Apr; 74(1):59-64. PubMed ID: 17298850
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a novel hepatitis B virus pregenomic RNA encapsidation inhibitor.
Jo E; Ryu DK; König A; Park S; Cho Y; Park SH; Kim TH; Yoon SK; Ryu WS; Cechetto J; Windisch MP
Antiviral Res; 2020 Mar; 175():104709. PubMed ID: 31940474
[TBL] [Abstract][Full Text] [Related]
8. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
Zoulim F; Berthillon P; Guerhier FL; Seigneres B; Germon S; Pichoud C; Cheng YC; Trepo C
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium carolinianum L.
Li J; Huang H; Feng M; Zhou W; Shi X; Zhou P
Antiviral Res; 2008 Aug; 79(2):114-20. PubMed ID: 18423640
[TBL] [Abstract][Full Text] [Related]
10. Antisense therapy of hepatitis B virus infection.
Offensperger WB; Offensperger S; Blum HE
Mol Biotechnol; 1998 Apr; 9(2):161-70. PubMed ID: 9658393
[TBL] [Abstract][Full Text] [Related]
11. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
12. Perspectives for the treatment of hepatitis B virus infections.
De Clercq E
Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
[TBL] [Abstract][Full Text] [Related]
13. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
Jacquard AC; Brunelle MN; Pichoud C; Durantel D; Carrouée-Durantel S; Trepo C; Zoulim F
Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
[TBL] [Abstract][Full Text] [Related]
14. Anti-HBV effect of individual traditional Chinese herbal medicine in vitro and in vivo: an analytic review.
Chen Y; Zhu J
J Viral Hepat; 2013 Jul; 20(7):445-52. PubMed ID: 23730837
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
Seignères B; Pichoud C; Martin P; Furman P; Trépo C; Zoulim F
Hepatology; 2002 Sep; 36(3):710-22. PubMed ID: 12198665
[TBL] [Abstract][Full Text] [Related]
16. 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.
Zoulim F; Dannaoui E; Borel C; Hantz O; Lin TS; Liu SH; Trépo C; Cheng YC
Antimicrob Agents Chemother; 1996 Feb; 40(2):448-53. PubMed ID: 8834896
[TBL] [Abstract][Full Text] [Related]
17. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
Seignères B; Martin P; Werle B; Schorr O; Jamard C; Rimsky L; Trépo C; Zoulim F
Antimicrob Agents Chemother; 2003 Jun; 47(6):1842-52. PubMed ID: 12760857
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro anti-hepatitis B virus activity of total phenolics from Oenanthe javanica.
Han YQ; Huang ZM; Yang XB; Liu HZ; Wu GX
J Ethnopharmacol; 2008 Jun; 118(1):148-53. PubMed ID: 18495393
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants.
Lam AM; Ren S; Espiritu C; Kelly M; Lau V; Zheng L; Hartman GD; Flores OA; Klumpp K
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559265
[TBL] [Abstract][Full Text] [Related]
20. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo.
Noordeen F; Vaillant A; Jilbert AR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5299-306. PubMed ID: 23939904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
